Summary
Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40% and significant alopecia in 30% of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of ≥ 10% but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T: Comparison of differential trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 10:385–395, 1987
Bonadonna G, Valagussa P, Zambetti M, Buzzoni R, Moliterni A: Milan adjuvant trials for stage I–II breast cancer. In: Salmon SE (ed) Adjuvant Therapy of Cancer V. Orlando, 1987, pp 211–221
Dalton WS, Brooks RJ, Jones SE, Salmon SE, Ketchel SJ, Giordano GF, Jackson RA, Mosley K, Slymen DJ: Breast cancer adjuvant therapy trials at the Arizona Cancer Center using adriamycin and cyclophosphamide. In: Salmon SE (ed) Adjuvant Therapy of Cancer V. Orlando, 1987, pp 263–269
Fisher B, Redmond CK, Wolmark N, NSABP invesigators: Long term results from NSABP trials of adjuvant therapy for breast cancer. In: Salmon SE (ed) Adjuvant Therapy of Cancer V. Orlando, 1987, pp 283–295
Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Hug V, Campos LT, Ames FC, Martin RG: Breast cancer adjuvant therapy trials of M.D. Anderson Hospital: results of three studies. In: Salmon SE (ed) Adjuvant Therapy of Cancer V. Orlando, 1987, pp 411–418
Bonadonna, G (ed) Advances in Anthracycline Chemotherapy: Epirubicin. Masson, Milan, 1984, pps 193
Armand JP: Phase II and phase III studies with epirubicin in breast cancer in France. In: Bonadonna G (ed) Advances in Anthracycline Chemotherapy: Epirubicin. Masson, Milan, 1984, pp 75–82
Armand JP, Hurteloup P, Bastit P, Chevallier B, Bonneterre J, Monnier A, Chauvergne J, Vo Van ML, Hayat M, Mercier M, Montcuquet P, Namer M, Roch H, Keiling R, Fargeot P, Fumeleau P, Weber C for the French Epirubicin Study Group (F.E.S.G.): Epirubicin in advanced breast cancer. Proc Am Soc Clin Oncol 6:65, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, S.E., Mennel, R.G., Peters, G.N. et al. Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer. Invest New Drugs 6, 195–198 (1988). https://doi.org/10.1007/BF00175397
Issue Date:
DOI: https://doi.org/10.1007/BF00175397